Of the 21 EGFR ex20ins patients with tumour PD-L1 expression of 50% or higher, 7 patients had received immunotherapy as monotherapy, 5 had received first-line pembrolizumab, and 2 had received pembrolizumab in the second-line or beyond setting. The gene discussed is EGFR; the disease is neoplasm.